ArticleClinical and translational allergy2023
Persistence in allergen immunotherapy: A longitudinal, prescription data-based real-world analysis.
Article in Clinical and translational allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Trial
- Patient-Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next-Generation Allergen Immunotherapy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Treatment of allergic rhinitis with allergen immunotherapy in children and adolescents-Adherence, rhinitis severity, and asthma onset.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Improvement of the therapeutic management of allergic patients in Europe - An expert think tank's position paper on allergen immunotherapy.The World Allergy Organization journal · 2025Review
- Atopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany.The World Allergy Organization journal · 2025Article
- Using mobile technology to increase adherence to sublingual immunotherapy: Real-world study with a new app/web platform AllergyVax®.The World Allergy Organization journal · 2025Article
- Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment.International journal of molecular sciences · 2025Review
- TAPAS-A Prospective, Multicentre, Long-Term Cohort Study in Children, Adolescents and Adults with Seasonal Allergic Rhinitis-Design and Early Results.Journal of clinical medicine · 2025Article
- Article
- Causes of Non-Adherence to Allergen-Specific Immunotherapy: A Foundation towards a Patient-Personalized Approach.Journal of personalized medicine · 2023Review
- Persistence in allergen immunotherapy: A longitudinal, prescription data-based real-world analysis.Clinical and translational allergy · 2023Article
- EUFOREA summit in Brussels 2023:Frontiers in allergy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAllergic rhinitis (AR) is a widespread disease with increasing prevalence in developed countries. The only treatment that tackles the underlying causes is allergen immunotherapy (AIT). This treatment is performed through two application routes, the subcutaneous immunotherapy (SCIT) or the sublingual immunotherapy (SLIT). However, persistence during the long course of treatment over 3 years is key for the efficacy of this treatment option. The impaired adherence significantly impacts public health resources. The aim of this study was to assess the persistence of AIT for both application routes.
methodsIQVIA
resultsThe number of patients included in the three allergen categories was 38,717 GP, 23,183 EFTP, and 41,728 HDM AIT. In all allergen categories and for any product group, patient persistence decreased with increasing age class with the difference between 5-11 years and 12-17 years greater than between the latter and 18+ years. The percentage of patients completing the first year of AIT was low, particularly for SLIT where 22.2%-27.1% of patients remained persistent after 12 months. The equivalent figures for dSCIT were 52.0%-64.1% and for oSCIT 38.3%-50.3%.
conclusionPersistence in AIT in AR was low in this retrospective prescription-based database and was clearly linked to patient age and application route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.